BridgeBio Pharma, Inc.
BBIO
$66.54
$2.013.12%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 502.08M | 353.78M | 235.81M | 127.42M | 221.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 502.08M | 353.78M | 235.81M | 127.42M | 221.90M |
| Cost of Revenue | 20.96M | 14.94M | 8.97M | 5.92M | 3.88M |
| Gross Profit | 481.11M | 338.84M | 226.84M | 121.50M | 218.02M |
| SG&A Expenses | 531.23M | 467.92M | 399.12M | 329.49M | 288.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.00B | 948.75M | 881.55M | 812.33M | 799.27M |
| Operating Income | -502.06M | -594.97M | -645.74M | -684.91M | -577.37M |
| Income Before Tax | -732.50M | -803.98M | -781.76M | -675.64M | -542.19M |
| Income Tax Expenses | 435.00K | 1.71M | 3.25M | 1.15M | 1.15M |
| Earnings from Continuing Operations | -732.94 | -805.69 | -785.01 | -676.80 | -543.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 8.01M | 8.57M | 8.59M | 8.83M | 7.59M |
| Net Income | -724.93M | -797.12M | -776.42M | -667.97M | -535.76M |
| EBIT | -502.06M | -594.97M | -645.74M | -684.91M | -577.37M |
| EBITDA | -496.63M | -589.60M | -640.23M | -679.15M | -571.29M |
| EPS Basic | -3.78 | -4.19 | -4.09 | -3.53 | -2.85 |
| Normalized Basic EPS | -2.21 | -2.48 | -2.60 | -2.67 | -2.24 |
| EPS Diluted | -3.78 | -4.19 | -4.09 | -3.53 | -2.85 |
| Normalized Diluted EPS | -2.21 | -2.48 | -2.60 | -2.67 | -2.24 |
| Average Basic Shares Outstanding | 766.07M | 761.95M | 758.61M | 755.68M | 744.24M |
| Average Diluted Shares Outstanding | 766.07M | 761.95M | 758.61M | 755.68M | 744.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |